Article
An alternative EGFR activation by patient-derived R252C mutation promotes cancer progression.
Nature communications - 21 Jan 2026
Zhang Yajuan, Fei Qizhen, Li Yan, Wang Siyao, Rong Tong, Wu Xueyuan, Gao Hong, Chen Chen, Gao Dong, Zhao Yun, Li Guohui, Chu Huiying, Li Wenfeng, Yang Weiwei
Abstract excerpt
Mutations in the extracellular or intracellular domains of epidermal growth factor receptor (EGFR) are implicated in the development of various cancers. While the intracellular mutations of EGFR have been extensively studied, the function of extracellular mutations remains poorly understood. In this study, we identify an EGFR mutant (EGFR R252C) in a patient with multifocal lung cancer and glioma, in which...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.